Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Cancer Res. 2019 Aug 15;79(19):5074–5087. doi: 10.1158/0008-5472.CAN-19-0244

Figure 4. Role of candidate drug resistance drivers in human melanoma patients.

Figure 4.

(A) Evaluation of the top vemurafenib resistance drivers in primary cutaneous melanoma samples from the TCGA-SKCM project. Over 37% of patient samples show increased expression of at least one of the candidate resistance drivers. (B) Expression of the candidate resistance drivers in an independent RNA-seq data set obtained from a cohort of 18 patients, each with a diagnostic sample (i.e. pre-treatment) matched with a second sample taken after progression on BRAFi therapy (35). (above) Six of the 18 patients had elevated expression of at least one resistance driver in the pre-treatment sample. An additional eight patients show over-expression of at least one candidate resistance driver in the progression samples.